STOCK TITAN
  1. Home
  2. News
  3. CVAC

CureVac N.V. - CVAC STOCK NEWS

Welcome to our dedicated news page for CureVac N.V. (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on CureVac N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CureVac N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CureVac N.V.'s position in the market.

News
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
Rhea-AI Summary
CureVac N.V. (CVAC) will announce its fourth-quarter and full-year 2023 financial results and business updates on April 24, 2024. The company, a global biopharmaceutical firm focused on mRNA-based medicines, will host a conference call and webcast on the same day. Investors can access the call via various dial-in numbers or the live webcast link on the CureVac website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Rhea-AI Summary
CureVac and MD Anderson have entered into a strategic collaboration to develop novel cancer vaccines. The agreement combines CureVac's mRNA capabilities with MD Anderson's research expertise to focus on hematological and solid cancers with high unmet medical needs. CureVac retains exclusive rights to late-stage development, commercialization, or partnering of the vaccine candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
News
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Rhea-AI Summary
CureVac (CVAC) announces positive interim data from Phase 2 study of seasonal flu vaccine candidate in collaboration with GSK. The candidate showed boosted antibody titers against all encoded flu strains across age groups. Geometric mean titers for influenza A strains exceeded licensed comparator vaccines, while those for influenza B strains were lower but in line with expectations. The platform demonstrated an acceptable safety profile, with plans for further optimizations to enhance immune responses against influenza B strains.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
clinical trial
News
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Rhea-AI Summary
CureVac N.V. (CVAC) Announces Positive Interim Data from Phase 2 Study of COVID-19 mRNA Vaccine Candidates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
clinical trial covid-19
-
News
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
Rhea-AI Summary
CureVac N.V. (Nasdaq:CVAC) announced that the German Federal Patent Court denied the validity of its patent EP 1 857 122 B1 after a nullity action filed by BioNTech SE. The decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering foundational as well as COVID-19-specific mRNA innovation. CureVac plans to appeal before the German Federal Court of Justice, remaining confident in the strength of its broad intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.55%
Tags
none
-
News
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
Rhea-AI Summary
CureVac N.V. (Nasdaq:CVAC) announced financial results for Q3 & first 9 months of 2023, along with business updates. Enrollment for Phase 2 COVID-19 study completed, flu Phase 2 study initiated, and Phase 1 study in glioblastoma on track. Preclinical data in oncology shows promising T cell responses. Infringement ruling on intellectual property rights postponed. RNA Printer® achieved first milestone for GMP-grade mRNA manufacturing. Chief Business and Commercial Officer to leave CureVac. Cash position of €464.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
earnings
News
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
Rhea-AI Summary
CureVac announces progress in its clinical vaccine development programs for COVID-19 and seasonal flu. The Phase 2 study for COVID-19 is fully enrolled with 427 participants, comparing mono- and bivalent vaccine candidates against a licensed comparator vaccine. Interim data is expected in early 2024. In the seasonal flu program, the Phase 2 study has started with a promising multivalent candidate. Data is expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
clinical trial covid-19
-
News
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Rhea-AI Summary
CureVac announces financial results for Q2 2023, initiates Phase 2 study in COVID-19, and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
earnings
-
News
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Rhea-AI Summary
CureVac N.V. (Nasdaq:CVAC) announced the initiation of a Phase 2 study for monovalent and bivalent modified mRNA COVID-19 vaccine candidates in collaboration with GSK. The study aims to evaluate safety, reactogenicity, and immune responses of single booster doses of the vaccine candidates. Enrollment has started at clinical sites in Australia, with an expected first data read-out in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
clinical trial covid-19
News
Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology
Rhea-AI Summary
Yarrow Biotechnology, Inc. has appointed Dr. Igor Splawski as Chief Scientific Officer. Dr. Splawski brings three decades of experience in genetic discovery and research and development of disease therapeutics. He has led teams that brought over 20 compounds to clinical trials, including 11 currently in phase I-III. Yarrow aims to develop nucleic acid therapeutics for severe CNS diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
Stock CVAC logo
CureVac N.V.

Nasdaq:CVAC

CVAC Rankings

#2867 Ranked by Market Cap
#3815 Ranked by Stock Gains
N/A Ranked by Dividends

CVAC Stock Data

651.62M
118.65M
45.43%
23.8%
2.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Tuebingen

About CVAC

founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o